Chimerix entered into an Amended and Restated Loan Agreement with Silicon Valley Bank for a $30 million credit facility on December 23, 2024. The facility includes a $20 million Tranche A available through February 2026 and a $10 million Tranche B through February 2027. The loans feature interest-only payments through March 2026, with potential extension to March 2027 upon meeting certain conditions.The company has submitted a new drug application (NDA) to the FDA for dordaviprone, targeting recurrent H3 K27M-mutant diffuse glioma treatment. With requested Priority Review, a potential PDUFA action date is expected in Q3 2025. Additionally, Chimerix has applied for a Rare Pediatric Disease Priority Review Voucher.The company has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, as confirmed by Nasdaq on December 24, 2024, following ten consecutive business days of meeting the threshold from December 10-23, 2024.

Chimerix entered into an Amended and Restated Loan Agreement with Silicon Valley Bank for a $30 million credit facility on December 23, 2024. The facility includes a $20 million Tranche A available through February 2026 and a $10 million Tranche B through February 2027. The loans feature interest-only payments through March 2026, with potential extension to March 2027 upon meeting certain conditions.The company has submitted a new drug application (NDA) to the FDA for dordaviprone, targeting recurrent H3 K27M-mutant diffuse glioma treatment. With requested Priority Review, a potential PDUFA action date is expected in Q3 2025. Additionally, Chimerix has applied for a Rare Pediatric Disease Priority Review Voucher.The company has regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, as confirmed by Nasdaq on December 24, 2024, following ten consecutive business days of meeting the threshold from December 10-23, 2024.